Who Paid My Doc
Jose Ruiz
Pediatric Emergency Medicine Aibonito, PR Medical Doctor
NPI 1548282379 CMS profile 521095
Calle Stanley Miller 11, Bo Caonilla, Aibonito, PR 00705
General payments
$148
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Jose Ruiz of Aibonito, PR is reported in the CMS Open Payments database as having received $148 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 64th percentile of Pediatric Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $70 | 1 | |
| 2023 | General | $77 | 1 |
Beside peers
- Jose Ruiz
- Pediatric Emergency Medicine median
- Middle half of Pediatric Emergency Medicine
- National median
In program year 2025, general payments to Jose Ruiz were reported at $0. Among 93 Pediatric Emergency Medicine profiles paid that year, the median was $58 and the middle half received between $26 and $151.
Show as a table
| Year | Jose Ruiz | Pediatric Emergency Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $62 | $20–$135 | $163 |
| 2020 | $0 | $37 | $19–$129 | $114 |
| 2021 | $0 | $52 | $17–$103 | $132 |
| 2022 | $0 | $89 | $25–$138 | $149 |
| 2023 | $77 | $52 | $25–$157 | $160 |
| 2024 | $70 | $85 | $24–$156 | $164 |
| 2025 | $0 | $58 | $26–$151 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
41
Drug cost
$217
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Omeprazole | Generic | 15 | $82 | |
| Allopurinol | Generic | 14 | $68 | |
| Famotidine | Generic | 12 | $67 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Emergency Medicine in Puerto Rico
Milagros Martin - Jimenez
Pediatric Emergency Medicine · San Juan, PR
Eddie Rodriguez
Pediatric Emergency Medicine · Ponce, PR
Sarah Marrero - Medina
Pediatric Emergency Medicine · Bayamon, PR
Mario Paulino Payano
Pediatric Emergency Medicine · San Juan, PR
Anita Diaz
Pediatric Emergency Medicine · San Juan, PR
Juan Zequeira Diaz
Pediatric Emergency Medicine · Bayamon, PR
Related records
Pediatric Emergency Medicine in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Emergency Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.